Population diversity in cancer treatment – differences matter
Recognising diversity is essential to providing effective, well tolerated and accessible cancer care globally
A little does not go a long way to treating cancer: updated ESMO study results cause concern about stalling progress in access to medicines
The updated Antineoplastic Medicine Survey (ANMS) dataset shows that essential therapies remain out of reach for patients in most low and lower middle-income countries despite international efforts
Choose the right treatment, at the right dose – a way to create a financially-sustainable cancer care?
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology
Wider implementation of precision oncology is still challenging
The 2024 TAT Honorary Awardee Prof. Funda Meric-Bernstam discusses progress made and how to overcome current obstacles in the field
WHO-ESMO collaboration sets accessible cancer care, prevention and education as priority areas of intervention
In the period 2024-2026, the technical collaboration between the United Nations agency and the Society plans a series of evidence-based activities to improve global cancer care
Cancer Research
Laying the foundations for next-generation precision oncology
Several ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world
Innovative approaches in the management of gastrointestinal cancers
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
A growing community
Teresa Del Giudice is the 30,000th ESMO Member. In this interview she explains what motivated her to join the community.
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices